Table 2.

Incidence of adverse events across all the groups by number of doses

		Group 1	Group 2	Group 3
Local adverse event
Pain
	1	6 (4%)	9 (6%)	3 (2%)
	2	3 (2%)	3 (2%)	0 (0%)
	3	0 (0%)	0 (0%)	0 (0%)
	4	4 (3%)	0 (0%)	0 (0%)
Redness
	1	2 (1%)	1 (1%)	0 (0%)
	2	10 (7%)	14 (10%)	2 (1%)
	3	2 (2%)	2 (1%)	1 (1%)
	4	3 (2%)	0 (0%)	0 (0%)
Swelling
	1	3 (2%)	5 (3%)	2 (1%)
	2	14 (9%)	23 (16%)	10 (7%)
	3	8 (6%)	11 (8%)	4 (3%)
	4	3 (2%)	0 (0%)	0 (0%)
Systemic adverse event
Fever
	1	14 (9%)	28 (19%)	13 (9%)
	2	18 (12%)	44 (30%)	7 (5%)
	3	18 (12%)	29 (20%)	16 (11%)
	4	19 (14%)	34 (25%)	8 (6%)
Irritability
	1	2 (1%)	5 (3%)	0 (0%)
	2	0 (0%)	4 (3%)	0 (0%)
	3	0 (0%)	0 (0%)	1 (1%)
	4	1 (1%)	1 (1%)	1 (1%)
Drowsiness
	1	0 (0%)	3 (2%)	1 (1%)
	2	2 (1%)	6 (4%)	2 (1%)
	3	0 (0%)	0 (0%)	0 (0%)
	4	0 (0%)	2 (1%)	0 (0%)
Loss of appetite
	1	1 (1%)	2 (1%)	1 (1%)
	2	0 (0%)	3 (2%)	1 (1%)
	3	0 (0%)	0 (0%)	0 (0%)
	4	0 (0%)	1 (1%)	1 (1%)

Data are n or n (%). Group 1 received 5 μg R21/25 μg Matrix-M, group 2 received 5 μg R21/50 μg Matrix-M, and group 3, the control group, received Rabivax-S. All solicited local and systemic adverse events were collected for 7 days after each vaccination. 150 participants in each group received the first dose of the vaccination. 149 participants in group 1, 147 participants in group 2 and 149 participants in group 3 received a second dose. 146 participants in group 1, 147 participants in group 2, and 149 participants in group 3 received a third dose. 132 participants in group 1, 138 participants in group 2, and 140 participants in group 3 received a fourth dose. Fever was defined as a temperature of 37·5°C or above. One participant in group 1 and one participant in group 2 had a severe fever (>39°C) after the third dose; all other adverse events were graded as mild or moderate. The grading of adverse events is given in the appendix (pp 13–91).